Pedro C. Barata
YOU?
Author Swipe
View article: Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617
Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 Open
Background 177Lu-PSMA-617 is approved for patients with metastatic castration-resistant prostate cancer (mCRPC). Although treatment is associated with improved outcomes, not all patients benefit and response is heterogeneous. We aim to cha…
View article: Molecular and clinical correlates of high <i>FOLH1</i> (PSMA) RNA expression in primary and metastatic prostate cancer
Molecular and clinical correlates of high <i>FOLH1</i> (PSMA) RNA expression in primary and metastatic prostate cancer Open
Background Prostate-specific membrane antigen (PSMA; FOLH1) is a cell-surface target for diagnostics and treatment in prostate cancer. We utilized a database of molecularly-profiled prostate tumors to evaluate clinical, genomic, and immuno…
View article: Efficacy of erdafitinib before or after enfortumab vedotin in <i>FGFR3</i> -altered advanced urothelial cancer: analysis of the UNITE collaborative study
Efficacy of erdafitinib before or after enfortumab vedotin in <i>FGFR3</i> -altered advanced urothelial cancer: analysis of the UNITE collaborative study Open
Background Erdafitinib is approved for locally advanced/metastatic urothelial cancer (LA/mUC). As enfortumab vedotin (EV) plus pembrolizumab enters frontline management, outcomes with erdafitinib pre- and post-EV are clinically relevant bu…
View article: Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the <scp>UNITE</scp> Study
Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the <span>UNITE</span> Study Open
Introduction Enfortumab vedotin‐ejfv (EV), an antibody–drug conjugate approved for advanced urothelial carcinoma (aUC), has limited real‐world safety data and no validated predictive biomarkers. Retrospective studies suggest higher objecti…
View article: 44Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC)
44Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC) Open
Background Tivo is a potent and highly selective VEGFR inhibitor designed to optimize VEGF blockade and minimize off-target toxicities. In TiNivo-2, patients with mRCC who had previous exposure to ICI, were randomized to receive study trea…
View article: 9Characterizing carbonic anhydrase 9 and HIF-2α RNA expression in clear cell renal cell carcinoma (ccRCC)
9Characterizing carbonic anhydrase 9 and HIF-2α RNA expression in clear cell renal cell carcinoma (ccRCC) Open
Background ccRCC is frequently driven by VHL loss, leading to HIF-2α stabilization and upregulation of downstream targets such as carbonic anhydrase 9 (CA9). While CA9 is a well-established diagnostic marker of HIF pathway activation, its …
View article: 2Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141)
2Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141) Open
Background Hypoxia-inducible factor 2-alpha (HIF-2α) is highly dysregulated in clear cell renal cell carcinoma (ccRCC), resulting in increased expression of proteins involved with angiogenesis, proliferation, and cancer cell survival. Casd…
View article: 46Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)
46Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC) Open
Background Tivo is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved in the US for treatment of patients with RCC following ≥2 prior systemic therapies. The approved Tivo monotherapy start…
View article: Addressing quality-of-life challenges for patients with end-stage metastatic castrate-resistant prostate cancer
Addressing quality-of-life challenges for patients with end-stage metastatic castrate-resistant prostate cancer Open
View article: Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials Open
Importance The impact of statins on overall survival (OS) in patients with prostate cancer treated using intensified therapy with apalutamide is not fully understood. Objective To determine whether statin exposure was associated with OS an…
View article: Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?
Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure? Open
The combination of enfortumab vedotin and pembrolizumab (EVP) has recently revolutionized care for patients with previously untreated locally advanced and metastatic urothelial carcinoma. However, predictive biomarkers of response, the opt…
View article: Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes
Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes Open
View article: HSD3B1 (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial Cancers
HSD3B1 (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial Cancers Open
HSD3B1 encodes an enzyme that catalyzes the conversion of adrenal precursors into potent sex steroids. A common germline variant (c.1100C) enhances this effect and is linked to breast cancer (BC) progression. As the HSD3B1 genotypes contri…
View article: REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens Open
The REnal cancer consortium for Focused Investigation of Novel biomarkers and Expression (REFINE) consortium represents an important initiative in integrating clinical data with molecular sequencing in patients with advanced renal cell car…
View article: Fibrotic Hypersensitivity Pneumonitis: A Diagnostic Challenge Leading to Lung Transplantation
Fibrotic Hypersensitivity Pneumonitis: A Diagnostic Challenge Leading to Lung Transplantation Open
Background/Objectives: Hypersensitivity pneumonitis (HP), a subtype of interstitial lung disease (ILD), is often misdiagnosed as idiopathic pulmonary fibrosis (IPF), particularly when the causative antigen cannot be identified. Typically r…
View article: Combination Therapy in Metastatic Hormone-Sensitive Prostate Cancer—Are We Moving Fast Enough?
Combination Therapy in Metastatic Hormone-Sensitive Prostate Cancer—Are We Moving Fast Enough? Open
View article: Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer Open
Despite several randomized controlled trials demonstrating the benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), a significant treatment gap persists. This initiative by the Prostate Cancer Foundat…
View article: Gender Disparities in Citations and Altmetric Attention Score in Oncology
Gender Disparities in Citations and Altmetric Attention Score in Oncology Open
PURPOSE Altmetric Attention Score (AAS) is a measure of the quantity of attention that a scholarly work receives, and evidence about gender gaps in AAS in oncology is lacking. Our objective was to analyze potential disparities in the AAS w…
View article: The Influence of the Germline HSD3B1 Adrenal-Permissive Allele (c.1100 C) on the Somatic Alteration Landscape, the Transcriptome, and Immune Cell Infiltration in Prostate Cancer
The Influence of the Germline HSD3B1 Adrenal-Permissive Allele (c.1100 C) on the Somatic Alteration Landscape, the Transcriptome, and Immune Cell Infiltration in Prostate Cancer Open
Background/Objectives: The germline polymorphism in the HSD3B1 gene (c.1100 C) results in adrenal-permissive (CC) or adrenal-restrictive (AA) functions of the protein product by regulating the production of high-affinity ligands that activ…
View article: Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial Open
Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6
View article: Table S8 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S8 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial Open
Table S8 shows Prevalence of adverse events
View article: Table S4 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S4 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial Open
Table S4 shows Adverse Events Included in the Co-primary Endpoint: Worst Grade by Patient
View article: Supplementary: Trial Protocol from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Supplementary: Trial Protocol from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial Open
Trial Protocol shows the details of the study
View article: Table S2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial Open
Table S2 shows Association of HDIVC Treatment with PSA Response Adjusting for Prior Docetaxel Exposure
View article: Table S17 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S17 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial Open
Table S17 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 6
View article: Table S3 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S3 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial Open
Table S3 shows Adverse Events Included in the Co-Primary Endpoint: All Occurrences
View article: Supplementary Methods from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Supplementary Methods from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial Open
Supplementary methods include study design and participants, outcomes and statistical analysis, FACT-P questionnaire, pharmacokinetics, and F2-Isoprostanes
View article: Table S13 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S13 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial Open
Table S13 shows Comparison of F2-Isoprostanes at Baseline between Treatment and Control Arms
View article: Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial Open
Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo
View article: Table S11 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial
Table S11 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial Open
Table S11 shows FACT-P Change (on Study Minus Baseline) Scores